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Abstract 
 
 
 
 
 
 
 
Carbamazepine is an early anticonvulsant still used today in the treatment of 
several forms of epilepsy. An active metabolite in the human body contributes to its 
pharmacological effect. Carbamazepine metabolism has high inter-individual 
variability, such that it is relatively difficult to establish a direct link between dose 
and concentration, or between concentration and pharmacological effect. 
Carbamazepine is thus a good candidate for therapeutic drug monitoring 
(TDM). Good UV specific absorbance and high plasmatic concentrations allow for 
the use of UV detection, which is often more accessible than other methods of 
detection. 
This paper presents several methods used for the detection of carbamazepine in 
plasma, methods that are capable of detecting drug and metabolites at adequate 
levels/ acceptance criteria. These methods have possible application not only in 
pharmacokinetic, bioequivalence, and permeability studies, but also in the 
therapeutic drug monitoring of carbamazepine. 
 
 
Acne conglobata is a rare, severe form of acne vulgaris characterized by the presence of comedones, 
papules, pustules, odules and som times hematic or meliceric crusts, loc ted o  the face, trunk, neck, arms 
and buttocks.  
 
Case Report 
We report the case of a 16 year old Caucasian female patient from the urban area who addressed our 
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Introduction 
Epilepsy is a common neurological disorder. The 
probability of an individual developing the disorder 
during a lifetime is between 3% and 5%. Newborn, 
children, and the elderly have the highest risk of 
developing epilepsy. An epileptic seizure is defined as a 
paroxysmal discharge of cerebral neurons, followed by 
obvious clinical phenomena: motor, sensory, and 
autonomic, with impairment or complete loss of 
consciousness. Epilepsy is defined as a condition 
characterized by repeating seizures (colloquially named 
“fits”). A patient should not be diagnosed with epilepsy 
until two such non-febrile seizures occur (1). 
TDM (therapeutic drug monitoring) may be defined 
as the use of drug or metabolite monitoring in body 
fluids as an aid to the management of therapy (the term 
therapeutic drug management is now also employed as 
an alternative description). Patients may need different 
doses of a drug to produce optimum pharmacological 
effects, as individuals vary widely regarding drug 
absorption, elimination (pharmacokinetics), and effect 
(pharmacodynamics) (2). The pharmacokinetics and 
pharmacodynamics steps involved in drug action are 
summarized in Figure 1. Most antiepileptic drugs meet 
the requirements for therapeutic drug monitoring (TDM) 
and thus are benefitted by this approach. 
 
 
Figure 1. Pharmacokinetics and pharmacodynamics 
steps involved in drug action; (2), adapted 
 
 
Carbamazepine, an iminostilbene drug substance 
from a chemical point of view, is effective against grand 
mal and all forms of epilepsy except petit mal. Its 
pharmacological action is similar to phenobarbital, 
phenytoin, lamotrigine, topiramate, and valproic acid, 
Figure 2, (3). It was initially approved in the U.S. for use 
as an anti-seizure agent in 1974. It has been employed 
since the 1960’s for the treatment of trigeminal neuralgia 
and is now considered a primary drug for the treatment 
of partial and tonic-clonic seizures (4).  
 
Figure 2. Carbamazepine chemical structure 
Therapy with antiepileptic drugs should commence 
only if the risk of future seizures on the patient’s health 
outweighs the risk of therapy. A premature start of 
antiepileptic therapy may expose the patient to 
unnecessary risk tied to the adverse effects of the drugs. 
Also the social consequences should not be overlooked, 
especially in the case of diagnostic errors (for example: 
the loss of the driver’s license) (5). On the other hand, 
waiting too long to treat must also be avoided. There are 
insufficient data to support the contention that seizures 
affect brain tissue and diminish cognitive capacity, but it 
is known that status epilepticus is a contributing factor to 
brain injury and death (1). 
However, the most compelling reasons to start 
antiepileptic treatment are the risk of personal injury, the 
risk of causing harm to others, and the psychosocial 
consequences of untreated epilepsy: low self-esteem, 
anxiety, and domestic and employment difficulties (1).  
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The choice of the drug used for treatment is 
determined mainly by its efficacy against the seizures 
and the potential adverse effects. Monotherapy is 
preferred.  
Carbamazepine (5H- dibenzo [b,f] azepin – 5 -
carboxamida) is a popular anticonvulsant and mood-
stabilizing drug used in Europe for many years (4). 
Reports of bone marrow suppression and leucopenia as 
adverse effects delayed the release on the US market 
until 1974, when it was approved for the treatment of 
trigeminal neuralgia. It has since become a first line drug 
against temporal lobe epilepsy and other convulsive 
disorders. It is a derivative of iminostilbene with a 
carbamyl group at the 5 position. The moiety is essential 
for the antiepileptic action (6). 
Carbamazepine is used mainly in the management of 
epilepsy, bipolar disorder, trigeminal neuralgia, 
attention-deficit hyperactivity disorder (ADHD), 
schizophrenia, complex regional pain syndrome, 
paroxysmal extreme pain disorder, neuromyotonia, 
disorder, borderline, and post-traumatic stress disorder 
(6). 
 
Discussion 
1. General data 
Pharmacokinetics 
The pharmacokinetics of carbamazepine are 
complex. They are influenced by its limited aqueous 
solubility and by the ability of many anti-seizure drugs, 
including carbamazepine itself, to increase their 
conversion to active metabolites by hepatic oxidative 
enzymes (4).  
Carbamazepine is slowly and erratically absorbed 
after oral administration with great inter-individual 
variability. Peak concentrations in plasma are usually 
observed 4-8 hours after oral ingestion, but may be 
delayed by as much as 24 hours, especially following 
administration of a large dose. It is moderately protein 
bound (65–85%) and is rapidly distributed to all tissues. 
Concentrations in cerebrospinal fluid (CSF) appear to 
correspond to the concentration of free drug in plasma 
(4). The drug exhibits auto-induction, which causes the 
initial low clearance rate to double or triple with 
continued exposure (1, 4, 6). 
Clearance is ensured by hepatic biotransformation 
(>99%) and to a small degree by renal excretion. 
Carbamazepine is metabolized by the hepatic 
microsomal enzymes system, through oxidation by the 
isoforms of cytochrome P450, followed by 
glucuronidation (3). 
Carbamazepine is metabolized in the liver by the 
isoenzymes CYP1A2, CYP3A4, CYP2C8 and CYP2C9, 
only two of which can be found in the transformation of 
other anti-epileptics (CYP3A4 and CYP2C9). The 
participation of such a high number of CYP isoforms 
implies numerous interactions with drugs from different 
therapeutic classes, through cross inhibition or induction 
(3).  
Carbamazepine decreases phenytoin metabolism due 
to competition for CYP2C9 isoform, but also by 
enzymatic inhibition, which leads to an increase in 
plasmatic concentrations, with an increase in toxicity 
(Figure 3). It also exerts enzymatic induction on the 
oxidative enzymatic systems dependent on cytochrome 
P450 and uridine glucuronyl transferase system (UGT). 
Carbamazepine reduces the effectiveness of valproic 
acid, clonazepam, ethosuximide, and lamotrigine (3). It 
also reduces its own metabolism. Thus, the half-life of 
carbamazepine is drastically reduced after repeated 
doses. Usually the half-life is between 12 and 24 hours, 
observed to be shorter in children than in adults (1). 
The main metabolite of carbamazepine is the 
pharmacologically active carbamazepine-10,11-epoxide. 
It is eliminated mainly as metabolites, through renal 
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excretion, with only a small part eliminated through 
feces. In children carbamazepine clearance is faster with 
a high accumulation of active metabolites (1, 3). Other 
metabolites identified in the urine include 
carbamazepine-N-glucuronide, iminostilbene, and 
several monohydroxy- and trihydroxy-carbamazepine 
isomers (7). 
 
    Figure 3. Carbamazepine metabolism 
Carbamazepine-10,11-epoxide is as active as the 
parent compound in various animals, and its 
concentrations in plasma and brain may reach 50% of 
those of carbamazepine, especially during the concurrent 
administration of phenytoin or phenobarbital. The 10,11-
epoxide is metabolized further to inactive compounds, 
which are excreted in the urine principally as 
glucuronides. Carbamazepine is also inactivated by 
conjugation and hydroxylation (7).   
 
Pharmacodynamics 
Carbamazepine stabilizes the neuronal membrane 
(blocking depolarization and hyperpolarization) by 
blocking the sodium channels, thereby increasing the 
excitability and convulsive threshold. It also reduces the 
discharge of pathologically modified neurons and limits 
cell depolarization inside the epileptic center (3). 
This effect appears to be mediated by a slowing of 
the rate of recovery of voltage-activated sodium 
channels from inactivation. These effects of 
carbamazepine are evident at concentrations in the range 
of therapeutic drug levels in the CSF of humans. The 
effects of carbamazepine are selective at these 
concentrations, in that there are no effects on 
spontaneous activity or on responses to iontophoretically 
applied GABA or glutamate. The carbamazepine 
metabolite, 10,11-epoxycarbamazepine, also limits 
sustained repetitive firing at therapeutically relevant 
concentrations, suggesting that this metabolite may 
contribute to the anti-seizure efficacy of carbamazepine 
(4). 
Toxicology 
Carbamazepine is chemically related to tricyclic 
antidepressants, like imipramine; thus it exhibits similar 
adverse effects: cholinergic effects, convulsions, and 
cardiac conduction anomalies. In severe intoxications, 
myoclonus, hypothermia, coma, and respiratory arrest 
may occur. Atrioventricular block and bradycardia have 
also been reported. It is highly hepatotoxic and can 
present teratogenicity (spina bifida and cardiac 
malformations) (3). 
During long-term therapy, the more frequent 
untoward effects of the drug include drowsiness, vertigo, 
ataxia, diplopia, and blurred vision. The frequency of 
seizures may increase, especially with overdose. Other 
adverse effects include nausea, vomiting, serious 
hematological toxicity (aplastic anemia, 
agranulocytosis), and hypersensitivity reactions 
(dangerous skin reactions, eosinophilia, 
lymphadenopathy, splenomegaly). A late complication 
of therapy with carbamazepine is retention of water, with 
decreased osmolality and concentration of Na+ in 
plasma, especially in elderly patients with cardiac 
disease (4). 
Carbamazepine induces hypersensitivity reactions 
that frequently involve the skin. Approximately 5-10% 
of patients taking carbamazepine experience cutaneous 
adverse drug reactions. Carriers of specific HLA variants 
are known to be susceptible to carbamazepine-induced 
hypersensitivity reactions. Therefore, HLA testing of 
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patients can identify those at-risk individuals so that an 
alternative drug can be used (8). 
Therapy and posology 
In epilepsy, carbamazepine is administered in doses 
of 0.8-1.2 g/day for 2-3 times a day for an adult and 0.1-
1 g/day (10-25 mg/kg/day) for children between 1 and 
15 years. The posology can be optimized by therapeutic 
drug monitoring (TDM) due to the good correlation 
between plasmatic concentration and therapeutic effect 
(3). 
Monitoring plasmatic concentration is feasible when 
deemed appropriate from clinical data. The therapeutic 
concentration interval is around 4 to 12 µg/mL (9). 
Because determination of free carbamazepine is more 
reliable, concentration in saliva and tears (where 
carbamazepine occurs in unbound form) has also been 
determined (1). 
However, there may be no simple relationship 
between the dose of carbamazepine and concentrations 
of the drug in plasma. Therapeutic concentrations are 
reported to be 6-12 μg/mL, although considerable 
variation occurs. Side effects referable to the CNS are 
frequent at concentrations above 9 μg/mL (4). During 
maintenance therapy carbamazepine absorption and 
clearance are highly variable and its elimination half-life 
may be longer than previously suspected. Sex and racial 
differences in clearance may contribute to variable 
dosing requirements and clinical response (10). 
Discontinuing treatment with carbamazepine is 
achieved by steadily reducing the dosage so as to avoid 
severe seizures (3). 
 
2. Therapeutic drug monitoring (TDM) 
Pharmacological effects can be measured with the 
use of markers—the response of the patient to the 
treatment. In clinical practice this is straightforward 
when the response is readily measurable. The response 
can be a clinical measure (e.g. blood pressure in the case 
of antihypertensive drugs) or may use an appropriate 
laboratory marker (e.g., glucose determination for 
hypoglycemic agents or cholesterol/triglycerides levels 
for lipid-lowering drugs) (2).  
Dose adjustment is much more difficult (but no less 
necessary) when drug response cannot be rapidly 
assessed clinically, which is the case for antidepressants. 
Under certain conditions and suitable analytical 
methods, plasma concentration of a drug and/or 
metabolite can be determined and may serve as an 
effective and clinically useful surrogate marker of the 
response. However, TDM is not just about the analytical 
result; rather it assumes multiple determinations at 
different moments, with the analytical results interpreted 
in order to make the best decision for the patient (2). 
The AGNP (Arbeitsgemeinschaft für Neuropsycho-
pharmakologie und Pharmakopsychiatrie) provides a 
consensus guideline regarding optimal use of TDM in a 
clinical context for psychotropic drugs. They note that 
the development of new, sensitive analytical techniques 
have shown that drug concentrations vary widely due to 
high inter-individual variability in the pharmacokinetics 
and pharmacodynamics of these drugs by correlating 
plasmatic concentration with dosage and adverse effects 
(11). The high inter-individual variability of plasma 
concentrations is also reported for different drugs, such 
as methotrexate, tamoxifen, methadone, and tramadol 
(12-14), as well as for metabolites used as biomarkers of 
exposure (i.e., cotinine). Such findings have encouraged 
clinicians to use TDM in combination with 
pharmacogenetic testing in order to demonstrate 
genetically determined metabolism (15-17). 
If plasma drug concentrations are to be a useful 
surrogate marker of response, two premises must be 
satisfied: 
- The drug concentration in plasma must accurately 
reflect the concentration at the site of action (the 
receptor). 
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- The drug concentration at the receptor should 
provide an accurate indication of the 
pharmacological response.  
The essential criteria for TDM to be clinically useful 
may be summarized as follows (2): 
 
 Poor correlation existing between the dose given and 
the plasma concentration obtained in different patients 
(wide inter-individual pharmacokinetic variability). 
 Good correlation existing between plasma 
concentration and pharmacological effect in different 
patients (low inter-individual pharmacodynamic 
variability); this also implies an established therapeutic 
range of plasma concentrations or a good relationship 
between plasma concentration and effect.  
 Clinically relevant only for drugs that show 
significant toxic or undesirable effects at plasma 
concentrations only slightly above those required for 
useful effect (low therapeutic index). 
 TDM is redundant for drugs where there is a better 
clinical marker of both the desired effect and any 
associated adverse effects. 
 Treatment is expected to be long-term. 
 
For effective TDM practice, analytical methods of 
adequate sensitivity are necessary to correctly evaluate 
the drug concentration levels in body fluids. Selectivity 
is also an issue due to co-medication (drugs administered 
simultaneously may interfere with the assay). Because 
carbamazepine is metabolized to an active compound, 
the challenge of developing a suitable method is even 
greater. In order to have all the information to assess 
pharmacological and toxicological effects, both the 
parent compound and the metabolite must be correctly 
assayed in order to make good decisions regarding 
patient therapy. 
 Plasma or serum samples are generally used for 
TDM. Chromatography is the most widely used method, 
high performance liquid chromatography (HPLC) or 
gas-chromatography (GC), coupled with various 
detectors: UV (although not very sensitive), 
fluorescence, MS, MS-MS, or nitrogen-phosphorous 
detectors for GC. Also, there is need for sample clean-
up—atime-consuming step—in order to remove matrix 
effects. 
Regarding the methods used in bioanalysis, the FDA 
(US Food and Drug Administration) has issued a 
guideline (Guidance for Industry – Bioanalytical method 
validation) in which general recommendations regarding 
method validation are presented. The information in the 
guidance applies to bioanalytical procedures and 
immunological and microbiological procedures that are 
performed for the quantitative determination of drugs 
and/ or metabolites as well as therapeutic proteins in 
biological matrices, such as blood, serum, plasma, urine, 
tissue, and skin (18).  
Validating bioanalytical methods includes 
performing all the procedures that demonstrate that a 
particular method used for quantitative measurement of 
analytes in a given biological matrix (e.g., blood, 
plasma, serum, or urine) are reliable and reproducible for 
the intended use. Fundamental parameters for this 
validation include the following: accuracy, precision, 
selectivity, sensitivity (limits of quantitation), 
reproducibility, and stability (18). 
 
3. Bioanalytical methods for determination of 
carbamazepine and metabolite 
In Table 1 the acceptance criteria for validation 
parameters of bioanalytical methods are presented. 
These criteria follow the Guidance for Industry – 
Bioanalytical method validation Draft Guidance from 
2013 provided by the FDA/CDER (18). 
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Table 1. Acceptance criteria for method validation parameters according to FDA/CDER Guidance for Industry (DRAFT) (18) 
Parameter Acceptance criteria 
Accuracy (recovery %) Recovery of 100%±15% (±20% for LLoQ) 
Precision (coefficient of variation CV %) Relative standard deviation of 15% (20% for LLoQ) 
Linearity and range Calibration curve with a correlation factor (R) NLT 0.999 
Selectivity 
No interference from biological matrix, metabolites and 
concomitant medication 
Limit of quantitation 
LLoQ an ULoQ (consistent with accuracy, precision and 
linearity) 
Stability Freeze and Thaw stability / Long-term stability 
The methods reported in the literature are mostly 
RP-HPLC (reversed-phase high performance liquid 
chromatography). The chromatographic columns, 
stationary phases, are C18 (octadecylsilane) and the 
mobile phases used are usually simple, polar, binary 
mixtures between water and an organic solvent 
(methanol or acetonitrile). Acidic modifiers are added in 
some methods: formic acid (19), phosphoric acid (20, 
21), acetic acid (22), or heptafluorobutyric acid (23). The 
elution system is isocratic, with one method reported to 
have gradient elution (23). Phosphate buffers of different 
pH are used as an aqueous mobile phase in some 
methods (24-28). 
Ternary mixtures are also widely used as a mobile 
phase(29, 30).One method reported the use of a 
diisopropyl-C14 column which is suitable for analyzing 
very basic and polar compounds (26). Gas-
Chromatography methods are not suitable for 
carbamazepine determination due to its susceptibility to 
thermal degradation. 
Detection is achieved by the use of 
spectrophotometric methods (UV) with various 
wavelengths, between 210 nm and 285 nm. MS-MS 
detection is also used in two of the methods (19, 22). UV 
detection is sufficient as the therapeutic ranges of 
carbamazepine and its metabolite are well within the 
sensitivity limits of UV detection. However, if a very 
specific method is required, MS detection can be 
employed. 
Regardless of the detection method used, sample 
preparation is a very important step. Sample cleanup is 
essential to lower the noise obtained in the 
chromatogram and to reduce potential damage done to 
various parts of the equipment. Methods used for sample 
preparation vary from liquid-liquid extraction (31-33), 
solid phase extraction (34), and protein precipitation (35-
37). All methods presented use plasma or other 
biological samples, although one method is used for 
carbamazepine determination in pharmaceutical 
formulations. This method however could be applied to 
biological fluids (38). 
Some methods have used internal standards for the 
evaluation of carbamazepine assay in the biological 
fluid, which is usually plasma. Some methods were used 
for cell permeability studies.Another chromatographic 
method reported for the assay of carbamazepine is 
HPTLC (high performance thin-layer chromatography), 
used for quantitation in formulation and for in-vitro 
dissolution studies (39). 
UV spectrophotometric methods have been reported 
for carbamazepine in pharmaceutical formulations (40, 
41). These methods are not applicable to biological 
samples because they fall short with regards to 
specificity: interference from sample matrix or co-
Cristian Tuchila et al. 
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medication is highly possible and differentiation 
between carbamazepine and metabolites is not possible. 
Immunoassays have also been reported for 
determination in plasma (31). In one case immunoassays 
were used to generate mathematical equations for 
determination of carbamazepine and its metabolite in 
plasma (19). 
Tables 2 to 5 present a summary of the 
chromatographic methods presented in this article. The 
parts left blank (with a dash) indicate that the validation 
parameter was either not performed or not reported. 
Also, where results reported in the articles did not 
match the parameters reported in the present tables, 
calculations were performed to standardize the values 
presented, in order to allow an objective comparison of 
the methods (e.g., if results for precision were presented 
as standard deviation and the average was also reported, 
a simple calculation was performed in order to report 
relative standard deviation in the tables). 
Results for accuracy are presented as minimum and 
maximum values obtained for inter-day and intra-day, 
where applicable. 
 
Table 2. Carbamazepine and metabolite determination by HPLC (I) 
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Table 3. Carbamazepine and metabolite determination by HPLC (II) 
Parameter 
(Reference) 
HPLC methods with UV detection 
(35) (21) (23) (33) 
Stationary phase 
– 
chromatographic 
column 
C18 C18 C18 C18 
Mobile phase 
Methanol:Water 
= 50:50 
A=Water pH=3 
(orthophosphoric acid) 
B=Acetonitrile:Methanol=50:5
0 
A:B=58:42 
Gradient 
A = 1% 
isopropanol + 
0.01% 
heptafluorobutyric 
acid in water 
B = 1% 
isopropanol + 
0.01% 
heptafluorobutyric 
acid in acetonitrile 
Water:Acetonitril
e=70:30 
 
Detection 285 nm 205 nm 280 nm 210 nm 
Internal standard Propylparaben - - 
Methyl-phenyl-
phenytoin 
Limit of 
detection 
- 0.67 μg/mL  0.03 μg/mL 0.15 μg/mL 
Limit of 
quantitation 
0.5 µg/mL 
2.24 μg/mL  0.10 μg/mL 0.3 μg/mL 
Linearity and 
range 
0.5 – 40 µg/mL 
5 - 100 μg/mL  0.993 - 198.6 
μg/mL  
0.3 - 20.0 μg/mL 
Precision 
(coefficient of 
variation CV %) 
<3.7% 0.15 - 1.13%  2.24%-3.78%  0.3 – 7.4%  
Accuracy 
(recovery %) 
97.53%-
103.58% 
99.79-101.23 98.69% 98.5% 
Sample 
preparation 
Protein 
precipitation 
- - 
Liquid-liquid 
extraction 
Sample type Plasma Permeability studies 
Permeability 
studies 
Plasma 
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Table 4. Carbamazepine and metabolite determination by HPLC (III) 
Parameter 
(Reference) 
HPLC methods with UV detection 
 
(37) (24) (36) (25) (26) 
Stationary phase – 
chromatographic 
column 
C18 C8 C18 C18 
Di-
isopropyl – 
C14 (Bonus 
RP) 
Mobile phase 
Methanol:Water 
= 50:50 
Acetonitrile : 
Isopropyl alcohol : 
phosphate buffer 
pH 3 = 36:15:49 
Methanol:Water 
= 50:50 
10 mM 
Phosphate 
buffer pH 7.0 : 
Acetonitrile = 
70:30 
Acetonitrile 
: phosphate 
buffer pH 
7.5 = 45:55 
Detection 285 nm 220 nm 285 nm 210 nm 241 nm 
Internal standard - 
Diclofenac 
sodium 
- Phenobarbital - 
Limit of detection - 0.05 µg/mL - 0.02 µg/mL 
0.006 
µg/mL 
Limit of quantitation 0.5 µg/mL 0.1 µg/mL 0.5 µg/mL 0.2 µg/mL 0.02 µg/mL 
Linearity and range 0.5 – 40 µg/mL 0.1 – 8.0 µg/mL 0.5 – 40 µg/mL 0.2 – 25 µg/mL - 
Precision (coefficient 
of variation CV %) 
2.42% – 11.79% 4.17% – 12.78% 2.42% – 11.79% < 7.96% 
6.2% - 
7.1% 
Accuracy (recovery 
%) 
93.18% – 
104.49 % 
85.00%–100.0% 
93.18% – 104.49 
% 
92.09% – 
108.5% 
78.8% – 
106.3% 
Sample preparation 
Protein 
precipitation 
Protein 
precipitation and 
liquid-liquid 
extraction 
Protein 
precipitation 
Solid-phase 
extraction 
Liquid-
liquid 
extraction 
Sample type Blood Plasma 
Intestinal sac 
samples 
Plasma Serum 
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Table 5. Carbamazepine and metabolite determination by HPLC (IV) 
Parameter 
(Reference) 
HPLC methods with UV detection 
 
(27) (22) (29) (30) (28) 
Stationary phase – 
chromatographic 
column 
C18 C18 C18 C18 C18 
Mobile phase 
5.2 mM 
Phosphate buffer 
pH 3 : 
Acetonitrile = 
70:30 
Water : Acetonitrile 
: Acetic acid = 74.5 
: 25 : 0.5 
Acetonitrile : Methanol 
: Water = 18 : 19: 63 
Water : 
Methanol : 
Acetonitrile = 
69 : 25: 6 
Phosphate buffer 
25 mM pH 4.6 : 
Methanol : 
Acetonitrile = 55 : 
35: 10 
Detection 237 nm MS (ion-trap) 210 nm 215 nm 235 nm 
Internal standard - Oxcarbamazepine  
10-11-
dihydrocarbamazepine 
Primidone - 
Limit of detection 0.0002 µg/mL - 
0.002 µg/mL for CBZ 
0.003 µg/mL for 
metabolite 
- 
0.0015 – 0.0016 
µg/mL 
Limit of 
quantitation 
0.0005 µg/mL 5.0 ng/mL 
0.01 µg/mL for CBZ 
0.005 µg/mL for 
metabolite 
0.01 µg/mL 0.005 µg/Ml 
Linearity and 
range 
0.0005 – 0.2 
µg/mL 
about 5.0 - 500.0 
ng/mL 
0.01 – 10 µg/mL for 
CBZ 
0.005 – 5 µg/mL for 
metabolite 
0.1 – 15 
µg/mL for 
CBZ 
0.1 – 5 
µg/mL for 
metabolite 
0.005 – 0.2 µg/mL 
Precision 
(coefficient of 
variation CV %) 
7.1% 0.74% - 3.81% 0.9% - 16.6% 0.8% - 17.3% 5.8% - 6.9% 
Accuracy 
(recovery %) 
78.6 % - 98.5%  94.65% - 104.28% 92.6% - 104.2% 
87.2% - 
%114.6  
95.8% - 98.0% 
Sample 
preparation 
Dispersive liquid-
liquid 
microextraction 
Protein 
precipitation 
Liquid-liquid extraction 
Liquid-liquid 
extraction 
Dispersive liquid-
liquid 
microextraction 
Sample type 
Plasma, urine and 
water 
Plasma Plasma Cell culture Plasma and urine 
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Conclusions 
 
The pharmacokinetics of carbamazepine are 
complex and are influenced by multiple factors such as 
its limited aqueous solubility and the ability of many 
anti-seizure drugs (including carbamazepine itself) to 
increase their conversion to active metabolites by hepatic 
oxidative enzymes.  
The methods described above have adequate 
sensitivity, capable of detecting carbamazepine and 
epoxy-metabolite at adequate levels, and fulfill all 
validation acceptance criteria. These methods should 
have applications not only in pharmacokinetic, 
bioequivalence and permeability studies, but also in the 
therapeutic drug monitoring. 
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